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Vascular endothelial growth factor A (VEGF) is involved in all the essential biology
of endothelial cells, from proliferation to vessel function, by mediating intercellular
interactions and monolayer integrity. It is expressed as three major alternative spliced
variants. In mice, these are VEGF120, VEGF164, and VEGF188, each with different
affinities for extracellular matrices and cell surfaces, depending on the inclusion of
heparin-binding sites, encoded by exons 6 and 7. To determine the role of each VEGF
isoform in endothelial homeostasis, we compared phenotypes of primary endothelial
cells isolated from lungs of mice expressing single VEGF isoforms in normoxic and
hypoxic conditions. The differential expression and distribution of VEGF isoforms affect
endothelial cell functions, such as proliferation, adhesion, migration, and integrity,
which are dependent on the stability of and affinity to VEGF receptor 2 (VEGFR2).
We found a correlation between autocrine VEGF164 and VEGFR2 stability, which
is also associated with increased expression of proteins involved in cell adhesion.
Endothelial cells expressing only VEGF188, which localizes to extracellular matrices or
cell surfaces, presented a mesenchymal morphology and weakened monolayer integrity.
Cells expressing only VEGF120 lacked stable VEGFR2 and dysfunctional downstream
processes, rendering the cells unviable. Endothelial cells expressing these different
isoforms in isolation also had differing rates of apoptosis, proliferation, and signaling via
nitric oxide (NO) synthesis. These data indicate that autocrine signaling of each VEGF
isoform has unique functions on endothelial homeostasis and response to hypoxia,
due to both distinct VEGF distribution and VEGFR2 stability, which appears to be,
at least partly, affected by differential NO production. This study demonstrates that
each autocrine VEGF isoform has a distinct effect on downstream functions, namely
VEGFR2-regulated endothelial cell homeostasis in normoxia and hypoxia.
Keywords: endothelial cells, hypoxia, VEGF isoforms, autocrine, endothelial adhesion, intercellular
communication, vascular assembly
INTRODUCTION
Vascular function is intimately connected to endothelial cell function, metabolism, and physiology:
vessel integrity is a function of endothelial cell behavior, which in turn affects simple morphological
and physiological parameters that impact on the response to organ demand, physiological context,
and environmental stress or disease (Ferrara et al., 2003; Coultas et al., 2005). It is thus no
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surprise that endothelial dysfunction underlies a myriad of
pathologies, or occurs as a consequence of unresolved organ
failure, such as what is seen in hypertension, diabetes, or
atherosclerosis (Carmeliet and Jain, 2000; Forstermann and
Munzel, 2006; Eelen et al., 2015).
Vascular Endothelial Growth Factor A (VEGF) is a major
regulator of endothelial cell (EC) function, by mediating
processes related to survival, proliferation, adhesion and
migration, all of which germane to functional and responsive
vasculature, and all occurring downstream of receptor activation:
VEGF receptor 1 (VEGFR1) is mostly involved with precursor
recruitment and intercellular communication, namely with
macrophages and monocytes, whereas VEGF receptor 2
(VEGR2) activity underlies endothelial-specific functions
(Olsson et al., 2006). VEGF was originally identified as a
heparin-binding polypeptide mitogen (Ferrara et al., 1991).
Molecular cloning reveals the existence of at least three species
of VEGF in mice, which are 120, 164, and 188 amino acids-long.
The mitogenic function of VEGF is conditioned by the affinity
of carboxyl-terminal domain to heparin (Keyt et al., 1996),
a factor that affects the secretion pattern and distribution of
individual isoforms. Isoforms that include a heparin-binding
domain encoded by exons 6 and 7 are cell-bound, as this domain
mediates VEGF binding to heparan sulfate proteoglycan proteins
and to cell surfaces (Ferrara et al., 1991; Park et al., 1993; Cohen
et al., 1995).
Low oxygen tension up-regulates VEGF in many types
of cells through increased stability of VEGF mRNA, as
well as through direct transcriptional regulation by hypoxia-
inducible transcription factors (Ikeda et al., 1995; Forsythe
et al., 1996). It has been asserted that both paracrine and
autocrine VEGF signaling is important for vascular modeling,
but the autocrine function of VEGF is essential for vascular
development and homeostasis (Lee et al., 2007). VEGF Isoforms
are generated through alternative splicing (Houck et al., 1991),
and can be produced in different ratios, depending on cell
type, organ or physiological setting, and varying between very
soluble (VEGF120) to membrane-bound (VEGF188), with the
most abundant isoform standing somewhere in-between and
co-existing in diffusible and bound forms (VEGF164) (Ng
et al., 2001). During embryonic development, VEGF188 is most
frequently detected in organs that are vascularized through
vasculogenesis (e.g., lung, heart, and liver) while the levels
of VEGF120 and VEGF164 are more abundant in organs
vascularized primarily through angiogenesis (e.g., brain, eye,
small intestine, and kidney) (Ng et al., 2001; Haigh, 2008).
More recently, VEGFxxxb isoforms have been described as
inhibitory or anti-angiogenic (Bates et al., 2002; Woolard et al.,
2009) and overexpressed as regulatory factors for their pro-
angiogenic counterparts, for example in involution of infantile
hemangioma (Ye et al., 2016) or thought to allow tumor
vascularization when downregulated in Renal Cell Carcinoma
(Bates et al., 2002). The xxxb variants, formed by distal splicing
of exon 8 of the VEGF gene, lack binding sites that allow
co-activation of multiple receptors, such as Neuropilin 1. These
are neither easily identified, nor appear to be present in most
healthy cells and tissues (Harris et al., 2012), which renders their
role more relevant in pathologic conditions. For that reason, we
did not include a scrutiny of inhibitory xxxb isoforms in this
study.
VEGF is required for survival in neonatal mice (Gerber
et al., 1999) and also endothelial VEGF null animals are
highly compromised during development (Lee et al., 2007).
A number of studies have clarified the role of each VEGF
isoform during early development by means of organ specific
analyses (Carmeliet et al., 1999; Mattot et al., 2002; Ruhrberg
et al., 2002; Stalmans et al., 2002; Zelzer et al., 2002; Maes
et al., 2004; Darland et al., 2011). Through those analyses, the
functional differences between soluble VEGF andmatrix-binding
VEGF in vascular development have been emphasized. For
instance, VEGF164 and/or VEGF188 are critical for myocardial
angiogenesis (Carmeliet et al., 1999), whereas VEGF164 is
sufficient for the developmental angiogenesis in mouse retina
(Stalmans et al., 2002). One of our preceding studies also
defined the functional differences and unique functions of each
VEGF isoform in tumorigenic neo-vascularization (Grunstein
et al., 1999). Additional evidence has shown that single VEGF
isoform-producing tumor cells have a distinct biological behavior
(Kanthou et al., 2014) and tumors respond differently to
anti-angiogenic therapy. Nonetheless, the role of these three
VEGF isoforms in autocrine homeostasis of endothelial cells is
not yet fully understood.
In this study, we used single VEGF isoform-expressing mice
and embryos to isolate primary pulmonary endothelial cells, and
investigated the influence of endogenous VEGF isoforms on cell
function and response to hypoxic stress. We show that individual
VEGF isoforms are uniquely associated with stabilization of
VEGFR2 and cell adhesion molecules under hypoxia, and
gained insight into the intracellular signaling pathways regulating
hypoxia responses and endothelial cell homeostasis downstream
of VEGF.
MATERIALS AND METHODS
Animals
All animals were housed in a UK Home Office guideline-
approved facility, and sample isolation from animals was
performed by a license holder in accordance with the UK Home
Office regulations under the Animals (Scientific Procedures) Act
1986. The strategies for generating VEGF120/120 mice (deletion
of exons 6 and 7), VEGF164/164 mice (deletion of exon 6), and
VEGF188/188 mice (containing all exons, except for exon 6b) have
been described by other groups previously (Carmeliet et al., 1999;
Stalmans et al., 2002).
Endothelial Cell Isolations and Culture
Mouse endothelial cells were isolated from lungs of VEGF164/164,
VEGF188/188, or littermate wild-type mice at the age of 8–12
weeks old, as previously described (Dong et al., 1997; Tang
et al., 2004; Branco-Price et al., 2012). VEGF120/120 endothelial
cells were isolated from lungs of E17.5 embryos due to the
occasional early birth from VEGF120/+ female of 18 dpc with
the high rate of perinatal deaths of those pups. WT cells from
E17.5 were also collected and characterized for proliferation and
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gene expression. Recombinant mouse VEGF164 protein (R & D
Systems, Minneapolis, MN, USA) was added as the supplement
for the VEGF120/120 endothelial cell culture for at least 7 days
after the isolation to rescue the suppressed proliferation. Cells
were cultured in endothelial cell growth medium, consisting
of low glucose DMEM:F12 with 1% penicillin/streptomycin,
1% nonessential amino acids, 2 mM sodium pyruvate, 20 mM
HEPES. Twenty percent fetal bovine serum (FBS) (Gibco) and 75
µg/mL endothelial mitogen (Alfa Aesar, Ward Hill, MA, USA)
were added for the complete growth medium.
Immunofluorescence
The expression and localization of VE-cadherin, β-catenin, and
Caspase-3/7 were visualized using immunofluorescence and
confocal microscopy (Leica CTR 6500). Cells were cultured on
the slide chamber coated with 0.1% gelatin (Sigma-Aldrich),
grown to confluence, and serum starved overnight, and then
put in hypoxia (1% oxygen, for up to 48 h) or kept in normal
oxygen tension for the same length of time. Cells were washed
and fixed with 4% paraformaldehyde for 10 min, permeabilized
with 0.5% Triton-X100 for 5 min, and blocked with 10% goat
serum (Sigma-Aldrich), or 10% donkey serum (Sigma-Aldrich),
or 3% bovine serum albumin (BSA) (Life Technologies) in
phosphate buffered saline (PBS) for 1 h, and incubated with
the following primary antibodies; anti-VE-cadherin (1:50, Santa
Cruz Biotechnology), anti- β-catenin (1:50, BD Transduction
Laboratories). Alexa Fluor 488- or 568-conjugated secondary
antibody (Life Technologies), and FITC-conjugated secondary
antibodies (Santa Cruz Biotechnologies) were used at 1:100.
Caspase-3/7 Green Flow Cytometry Assay kit (Thermo Fisher)
and NucRed 647 (Life technologies) was used for Caspase-
3/7 staining and counterstaining of nucleus, according to the
manufacture’s protocol.
Cell Proliferation Assay
Each VEGF isoform cell colony was seeded at density of
2.0 × 104/mL in a 24-well plate with complete culture medium
(containing 20% FBS) or reduced serum (containing 2% FBS),
or 0.1% BSA containing basal medium. For the analysis of cell
proliferation under hypoxia, hypoxic treatment was started 24
h after plating. Data were collected from three wells per each
genotype, each isolated from three mice.
Migration Assay
To assess cell migration, wound-healing assay was performed
as previously described (Yamamoto et al., 2010). The cells were
plated on 10 ng/mL fibronectin (Biomedical technologies)-coated
6-well plates. The monolayer of endothelial cells was scratched
manually with a plastic pipette tip. After washing with PBS, the
wounded monolayers of cells were allowed to heal for 24 h under
hypoxia (1% O2) in the serum-free culture medium. The length
of the wounds was measured and expressed as the relative folds
to the migration distance of the wild type.
Adhesion Assay
Twenty-four-well, non-tissue culture-treated plates were coated
with 10 ng/ml fibronectin (Biomedical technologies) for 2 h at
37◦C. 1.0 × 105 cells suspended in 200 µL serum free media
were added to each well and incubated at 37◦C for 30min.
The supernatant was removed and adherent cells were selected
by washing with PBS. Three wells per group were incubated
for 5 min with 0.1% crystal violet in 20% methanol and then
washed three times with PBS. Crystal violet contained in the
adhesive cells was extracted in 50% ethanol and quantified by the
absorbance at 590 nm.
Permeability Assay
Endothelial cells were seeded at the density of 1 × 105 cells into
COSTAR transwell (6.5 mm diameter, 0.4 µm pore, Corning, cat
no. 3413). Cells were grown for 4 days and then pre-incubated at
21 or 1% O2 for 3 h. HRP-conjugated streptavidin (1×, Abcam)
was then added to the top of the upper chamber; after 1 h, 100
µL of medium was collected from the lower chamber, and the
level of HRP-streptavidin in the lower chamber was measured
by mixing the 100 µL medium with equal volume of 3,3′,5,5′-
tetramethylbenzidine (TMB) peroxidase enzyme immunoassay
substrate (Abcam), incubated for 30 min before the addition of
50 µL of Stop Solution (Abcam). The absorbance of the solution
was measured at 450 nm.
Transendothelial Migration Assay
Transendothelial migration of GFP-labeled Lewis Lung
Carcinoma cells (LLCGFP) was analyzed, as previously described
(Branco-Price et al., 2012) with some modifications. Endothelial
cells were seeded on COSTAR transwell inserts (6.5 mm
diameter, 8 µm pore; Corning, cat no. 3422) at cell density
of 2.0 × 104 per well, and grown for 5 days. LLCGFP cells,
pre-stained with Calcein-AM dye (BD Bioscience), were seeded
on the endothelial monolayer and the inserts were incubated at
37◦C for 24 h under hypoxia (1% O2), with serum-free media on
both upper and lower chambers. Migrated cells were counted in
five random fields per insert at 100x magnification by using the
fluorescent stereomicroscope (Leica M165FC).
Tube Formation Assay
In vitro tube formation on Matrigel was analyzed, as previously
described (Tang et al., 2004), with some modifications: Growth
Factor Reduced Matrigel (BD Biosciences) was applied at 60
µL/well in 96-well plates and incubated at 37◦C for 30 min
to allow hardening. 6.0 × 103 primary lung endothelial cells
medium containing 0.5% serum, were seeded on top of the
Matrigel. Plates were incubated under normoxia or hypoxia (1%
O2) at 37
◦C for 9 h. Cells were stained with Calcein AM dye
(BD Bioscience) at the end of the incubation, and parameters
of detected networks were analyzed using Image J software
(Angiogenesis Analyzer, created by Gilles Carpentier).
Quantification of NO Levels
Culture medium collected from the primary endothelial cells
at the time point of 48 h under hypoxia at 1% oxygen or
under normoxia were analyzed using an NOA280i (Siever,
GE Healthcare) according to the manufacturer’s instructions.
Readings were performed a minimum of three times for each of
three wells.
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Collection of Extracellular Matrix Fraction
Extracellular matrix was prepared from a culture dish, as
previously described (Yamamoto et al., 2009) with the following
modifications: Total cell lysates in 100mm dishes had been
collected in 500 µL RIPA buffer [10 mM Tris/HCl pH 8.0,
150 mM NaCl, 5 mM EDTA, 0.5% Sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 1% TritonX-100] supplemented
with protease inhibitors (Roche). Extracellular matrix remaining
on the dish was extracted at 100◦C for 5 min in 375 µL of LDS
Sample buffer (1x, Invitrogen) after washing with PBS and RIPA
buffer three times.
Semi-Quantitative qPCR
Total RNA was extracted using RNeasy Mini Kit (QIAGEN) and
converted into cDNA from 0.5 µg or 1 µg of total RNA using
Superscript III (Invitrogen) according to the manufacturer’s
protocol. cDNA was amplified in SYBR Green with an ABI
Prism system (Applied Biosystems). Forward and reverse primers
were as follows: integrin alpha V 5′-AGGCTGGAACTCAA
CTGCTC-3′, 5′-TTGGCCCGTCAATGTCGTAA-3′; integrin β
3 5′-GCCTTCGTGGACAAGCCTGT-3′, 5′-GGACAATGCCTG
CCAGCCTT-3′; β-actin 5′-CCCAGAGCAAGAGAGG-3′, 5′-
GTCCAGACGCAGGATG-3′. Results were normalized to β-
actin mRNA levels.
Reagents and Antibodies
1400 W and LY294002 were purchased from Sigma-Aldrich
and Cell Signaling Technology, respectively. VEGF Mouse Elisa
kit (Abcam, cat no. ab100751) was used for the quantitative
analysis of VEGF in culture medium. Anti-VEGFR2 (D5B1, Cell
Signaling Technology, 9698) antibody and Protein A/G agarose
(Santa Cruz Biotechnology, sc-2003) were used for VEGFR2
immunoprecipitation. The detail of primary antibodies used for
western blot or immunofluorescence analyses are as following;
VEGF (P-20, Santa Cruz Biotechnologies, sc-1836), VEGFR2
(D5B1, Cell Signaling Technology, 9698), VE-cadherin (Santa
Cruz Biotechnology, sc-6456), β-actin (A5316, Sigma-Aldrich),
α-phosphotyrosine (4G10, Millipore, 05-1050), phospho-AKT
(Ser 473, Cell Signaling Technology, 9271), phospho-AKT
(Thr 308, Cell Signaling Technology, 13038), β-catenin (BD
Transduction Laboratories, 610153), PECAM-1 (M-20, Santa
Cruz Biotechnology, sc-1506), ICAM-1 (M-19, Santa Cruz
Biotechnology, sc-1511), VCAM-1 (Abcam, ab174279).
Statistical Analyses
Each experiment was performed isolating from at least two
different animals per group and three technical replicates.
The statistical significance was assessed by Student’s t-test and
expressed as average± SEM. P< 0.05 was accepted as significant.
RESULTS
VEGF Isoforms Differentially Regulate
Endothelial Cell Proliferation and Viability
under Hypoxia
To investigate the differential roles of endogenous VEGF
isoforms on endothelial cell (EC) viability under hypoxic stress,
we purified ECs from mice expressing exclusively one of the
isoforms. We started by monitoring the proliferation rates of
cells expressing single isoforms, and our first observation was
that EC expressing single VEGF120 (VEGF120 EC) displayed
severely suppressed proliferation in all tested conditions
(Figure 1A), for which reason it was not included in these
panels. Characterization of growth was therefore carried out
solely on VEGF164 EC and VEGF 188 EC, and cell proliferation
was quantified over a range of serum concentrations. We see
that autocrine expression of VEGF164 conferred a significant
proliferative advantage; the maximal difference between
VEGF164 EC and other cells was noted at 96 h of hypoxic culture
(Figure 1A).
The proliferation of VEGF188 EC was stalled after 48 h
without serum (Figure 1A, far right panels). Another measure
of viability can be the rate of spontaneous apoptosis, which
was visualized by Caspase-3/7 staining, and demonstrates that
VEGF188 EC aremore apoptotic thanVEGF164 EC, and that this
difference is exacerbated by hypoxia, where there is a five-fold
higher frequency of apoptotic cells in VEGF188 than in VEGF164
EC populations (Figure 1B). This is consistent with previous
knowledge that themitogenic activity of VEGF relies on its ability
to effectively bind heparin (Keyt et al., 1996; Ferrara, 2010) and,
consequently, cell surfaces and receptors, and explains why EC
expressing exclusively VEGF120, which exists only as a soluble
and diffusible signal (Supplementary Figure 1) do not proliferate
and are only partially sustained in culture with supplementation
of a potent mitogenic isoform, VEGF164.
Vascular Endothelial Growth Factor
Receptor 2 Stability in Hypoxia Is
Differentially Affected by Individual VEGF
Isoforms
VEGF exerts its effects by binding to multiple receptor tyrosine
kinases, VEGF receptor 1, 2, and 3 (VEGFR1-3), and co-
receptors such as Neuropilins 1 and 2. VEGFR1 is a regulator
of VEGFR2 signaling capacity, whereas VEGFR3 is associated
with lymphangiogenesis by VEGFC and D (Olsson et al., 2006).
VEGFR2 is implicated in all aspects of normal and pathological
vascular endothelial-cell biology, and its expression is restricted
to endothelial cells (Olsson et al., 2006). It has also been shown
that VEGFR2 expression increases in response to hypoxia via
a hypoxia-inducible factor (HIF)-1α-driven, VEGF-mediated
autocrine loop on EC (Tang et al., 2004). Protein levels of
VEGFR2 in EC under normoxia were evaluated by western blot
analysis of total cell lysates of EC isolated from each genotype,
as shown in Figure 1C. We used fresh isolates of VEGF120
EC to investigate the levels and activation of VEGFR2 in these
cells, and strikingly, EC expressing exclusively VEGF120 were
also unable to stabilize VEGFR2, in agreement with their failure
to divide. WT EC purified from E17.5 littermates proliferated
normally (not shown) and expressed normal levels of VEGFR2
(Supplementary Figure 2). VEGF164 is found in conditioned
medium and cell lysates, and VEGF188 almost exclusively bound
to extracellular matrix (Supplementary Figures 1, 3). VEGFR2
is most abundant in normoxic VEGF164 EC, which is also the
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FIGURE 1 | Contribution of specific VEGF isoforms to endothelial cell viability and autocrine signaling. (A) Endothelial cell viability was measured in
wild-type (WT) endothelial cells and cells expressing each of the VEGF isoforms 164 or 188, in normoxia (21% O2, top panels) and hypoxia (1% O2, bottom panels),
for 96 h. The culture media containing 20% FBS (high serum), 2% FBS (low serum), or 0.1% BSA (no serum) were replaced at the time points of 24 h after cell plating.
Data shown are average cell number (per well) ± SEM (n = 3); three wells, each containing cells from 2 to 3 mice. (B) EC of different genotypes were stained for
Caspase 3/7 to assess relative levels of apoptosis in normoxia (top) and after 48 h of hypoxia (bottom), scale bar, 100 µm. Right Panel shows ratio of
caspase-3/7-positive cells out of total cells (caspase-3/7-positive and NucRed Live 647-positive cells). Data represents average ± SEM (n = 3); three fields, each
containing cells from 2 animals, *P < 0.05. (C) VEGFR2 protein abundance was assessed by western blot of whole cell extracts (left). Quantification is shown in the
panel on the right. (D) Activation of VEGFR2 was assessed by immunodetection of P-Tyr in total VEGFR2 protein obtained by immunoprecipitation (IP); representative
blot shown on the left and quantification data on the right.
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only genotype where hypoxia-dependent induction of VEGFR2
is observed. On the other hand, tyrosine phosphorylation of
VEGFR2 (normalized to total VEGFR2 levels) was equivalent in
both VEGF164 EC andVEGF188 EC under hypoxia (Figure 1D).
This is an indication that autocrine VEGF164, but not VEGF188,
is necessary for the hypoxia-induced up-regulation of VEGFR2,
whereas the phosphorylation of VEGFR2 under hypoxia is not
necessarily correlated with VEGFR2 levels. We do see an increase
in P-VEGFR2 in WT cells in response to hypoxia, suggesting
that both VEGF164 and VEGF188 are required for the increased
activation levels of this receptor in response to hypoxia.
Hypoxic Endothelial Cells Expressing Each
VEGF Isoform Differ in Morphology and
Barrier Function
To investigate the distinct autocrine roles of each VEGF isoform
on endothelial barrier function, morphology and expression
levels of cell junctional architecture was assessed and compared
in each culture. At endothelial adherens junctions, VEGFR2
coexists with β-catenin and vascular endothelial (VE)-cadherin,
known to regulate the half-life and the internalization of VEGFR2
(Calera et al., 2004; Lampugnani et al., 2006). VEGF signaling
itself also induces the endocytosis of VE-cadherin (Gavard and
Gutkind, 2006). We see the highest levels of VE-cadherin in
VEGF164 EC during the 48-h course of hypoxia, and the lowest
in VEGF120 EC (Supplementary Figure 4). β-catenin levels, also
induced by hypoxia, were elevated in both VEGF164 EC and
VEGF188 EC, and maintained at high levels throughout the
hypoxic treatment, whereas the induction of this protein in WT
EC is transient, decreasing after the 8 h time point. Lowest
levels of this protein were found in VEGF120 EC (Supplementary
Figure 4).
The morphology of EC expressing individual VEGF isoforms
was investigated by immunofluorescent (IF) staining of VE-
cadherin and β-catenin (Figures 2A,B). VEGF164 EC and WT
EC formed a cohesive and uniform monolayer. In contrast,
VEGF188 EC displayed a more mesenchymal appearance
with elongated, spindle-shaped cells with extended processes,
correlated with little cell-cell association. Furthermore, VE-
cadherin of VEGF188 EC was ectopically internalized instead
of being localized to the cell surfaces (Figure 2A). In hypoxia,
only WT EC showed increased signal for VE-cadherin, implying
that hypoxia induction of VE-cadherin levels or increased
network formation may require the concomitant expression of
all VEGF isoforms (Figure 2A). β-Catenin IF also showed close
longitudinal alignment along EC in VEGF164 EC, localizing to
the cell membrane. Instead, in VEGF188 EC, β-catenin was seen
in the nucleus (Figure 2B). In hypoxia, cytosolic β-catenin levels
were increased in all EC lines, including WT (data not shown).
The hypoxia-driven increase in endothelial permeability was
more pronounced in VEGF188 EC than in VEGF164 EC
(Figure 2C), with WT EC showing the lowest paracellular
permeability, an indication that all three VEGF isoforms are
required for effective EC barrier function. PECAM-1, classically
involved in several types of EC adhesion junctions, was most
abundant in VEGF164 EC (Supplementary Figure 4). Similarly,
VEGF188 EC monolayers were more permissive to tumor cell
migration (LLCGFP) than VEGF164 ECmonolayers (Figure 2D).
Endothelial VEGF164 and VEGF188 Are
Differentially Necessary for
Hypoxia-Induced Tube Formation
We next investigated angiogenic potential in each type of EC
by performing adhesion, migration, and network formation
assays. Previous studies, which analyzed vascular development
and angiogenesis of mouse embryos expressing only VEGF120,
underscored the importance of matrix-binding isoforms,
VEGF164 and/or VEGF188, for cardiovascular development
(Carmeliet et al., 1999; Ruhrberg et al., 2002; Van Den Akker
et al., 2007, 2008). The adhesion of EC toward the extracellular
matrix protein fibronectin was significantly higher in VEGF164
EC and lower in VEGF188 EC, when compared to that of WT
(Figure 2E). In scratch assays on fibronectin-coated plates,
hypoxic VEGF188 EC showed decreased cell migration relative
to WT and VEGF164 EC (Figure 2F). Integrin β3 subunit, a
component of the binding structure to fibronectin, was up-
regulated by hypoxia in VEGF164 EC (Supplementary Figure
5), suggesting that VEGF164 is more critically involved in cell
adhesion and migration of EC than VEGF188.
To determine the role of specific isoforms in angiogenesis,
each EC genotype was plated onto Growth Factor Reduced
Matrigel and allowed to self-organize into capillary-like
structures. The basal angiogenic potential in normoxia was
higher in VEGF188 EC than in VEGF164 EC (Figures 3A,B),
with VEGF188 EC extending with more frequent junctions
and mesh-like structures in normoxia than VEGF164 EC
(Figures 3A,B). In contrast, formation of capillary-like mesh
structures, induced by low oxygen tension, was profound
in VEGF164 EC but not in VEGF188 EC (Figures 3A,B),
suggesting the differential importance of VEGF164 and
VEGF188 on network maturation under hypoxia and normoxia,
respectively, due to distinct molecular characteristics.
VEGF188, but Not VEGF164, Is Associated
with Hypoxia-Induced Nitric Oxide
Production via PI3K/Akt Pathway
Nitric Oxide (NO) is a bioactive modulator of various types
of cells leading to the regulation of vascular tone, immune
response, and synaptic neurotransmission (Napoli et al., 2013).
It is known that endogenously produced NO can increase
endothelial cell permeability, and suppress cell proliferation
through cell cycle arrest of EC (Tanner et al., 2000; Villalobo,
2006). Endothelial NO synthase (eNOS) is a fundamental
determinant for physiological NO production in EC. eNOS is
activated by the serine/threonine protein kinase Akt/PKB and
is up-regulated by VEGF (Bouloumie et al., 1999; Dimmeler
et al., 1999). We have shown that NO production by EC in
hypoxia is significantly increased by activation of the inducible
NOS isoform (iNOS), a target of HIF-1α (Branco-Price et al.,
2012). To investigate the role of VEGF isoforms in hypoxia-
induced NO production by EC, we measured accumulation
of NO in EC-conditioned media. NO was detected in all
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FIGURE 2 | Endothelial integrity as a function of isoform-specific VEGF signaling. (A) Normoxic and hypoxic (1% O2, 24 h) EC were fixed and immunostained
with VE-cadherin and (B) β-catenin antibodies and detected by immunofluorescence. Targets are shown in green, nuclei in red; scale bars, 25 µm. (C) EC monolayers
were grown in 0.4 µm pore Boyden chamber filters. To assess paracellular permeability, normal medium was replaced with medium containing HRP-streptavidin (∼100
kDa), which was quantified in the lower chamber 1 h after normoxic or hypoxic incubations using a peroxidase-coupled assay; data shown are absorbance values at
450 nm. (D) Tumor cell invasion assay: GFP-labeled Lewis Lung Carcinoma cells (LLCGFP) were seeded over endothelial monolayers in 8 µm pore filters; fluorescent
cells were counted on the opposite side of the filter after 24 h at 1% O2. Results shown in (C) and (D) are average ± SEM (n = 3); three wells isolated from three mice
per each group. (E) A suspension of 1.0 × 105 endothelial cells was seeded onto fibronectin-coated plates and washed with PBS 30 min later. Adherent cells were
stained with Crystal Violet, which was subsequently extracted and quantified by spectrometry. Results shown are average ± SEM (n = 3); three wells, each containing
cells isolated from 2 to 4 mice. (F) Scratch assay performed on endothelial cell monolayers, and cell migration was quantified 24 h after monolayer disruption by
measuring scratch width after 24 h in at 1% O2. Results shown are average ± SEM (n = 4); four fields, each of cells isolated from 2 to 4 mice. *P < 0.05, **P < 0.005.
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FIGURE 3 | VEGF isoform contribution to endothelial network
formation. (A) Tube formation assay on growth factor-reduced Matrigel. Cells
were incubated for 9 h in 21% O2 or 1% O2 and resulting networks were
visualized with Calcein AM live cell staining. Scale bars, 500 µm. (B)
Quantification of different parameters of endothelial networks by Image J
software, shown as average ± SEM (n = 3); three fields, each group of cells
obtained from 2 to 3 mice. *P < 0.05, **P < 0.005.
types of EC under normoxia, and the hypoxia-induced NO
production was significant only in VEGF188 EC and WT EC,
whereas VEGF164 EC did not show any increments of NO by
hypoxia (Figure 4A). Treatment with LY294002, an inhibitor
of phosphatidylinositol-3-OH kinase (PI3K), attenuated the
hypoxia-induced NO release from VEGF188 EC and WT
EC, but had no effect on the NO production by VEGF164
cells (Figure 4A), indicating the possible relationship between
hypoxia-induced NO production of EC and activated PI3K under
autocrine VEGF188. As the downstream molecules of PI3K
pathway, hypoxia-induced phosphorylation of Akt at Ser473 was
highest in VEGF188 EC (Figure 4B). Phosphorylation of Akt
at Thr308 was not promoted by hypoxia (data not shown).
Treatment with 1400W, an iNOS-specific inhibitor, cumulatively
increased hypoxia-mediated VEGFR2 stability (Supplementary
Figure 6). These data indicate that each VEGF isoform acts
distinctly on hypoxia-dependent stabilization of VEGFR2, and
the underlying process is, at least partially, a consequence of
differential NO production, as a result of altered PI3K/Akt
activation.
DISCUSSION
In this this paper we focused on the role of isoforms VEGF120,
164 and 188 in vascular endothelium homeostasis, which
includes their response to hypoxia: in these cells, the ability
to sense, withstand and respond to a wide range of oxygen
concentrations is key to their ability to perform functions and
rescue organs and tissues during insults such as altitude, vascular
occlusion, or hypertension (Tretyakov and Farber, 1995; Ten
and Pinsky, 2002); the endothelial response underlying the
vascular remodeling are what allow subsequent tissue endurance.
We hypothesized that the plasticity of endothelial metabolism
includes the control of the ratio of the VEGF isoforms in the
endothelium, such as what was shown in lung epithelium during
pulmonary injury (Medford et al., 2009).
While characterizing the distribution of VEGF isoforms, we
showed that all isoforms are induced by hypoxia: VEGF120,
the smallest and most diffusible isoform, as expected, is only
present in conditioned media (Supplementary Figure 1), whereas
VEGF164 is found in all fractions, confirming that this isoform
the most ubiquitous, and found in diffusible, cell- and matrix-
bound, whereas VEGF188 appears mostly in the extracellular
matrix (Supplementary Figures 1, 3).
What appears to be the most striking effect of this differential
distribution is the autocrine activation of VEGFR2, the main
receptor involved in EC function. VEGF is known to cause
VEGFR2 accumulation and activation (Lee et al., 2007), as
seen in the typical hypoxia response (Tang et al., 2004),
but VEGF120 alone is unable to drive this process, and
even significantly increased levels of this isoform, such as
observed during hypoxia exposure (Supplementary Figure 1),
are not enough to promote VEGFR2 stabilization, resulting
in unviable homozygous offspring in VEGF120 animals, and
in inability to maintain proliferation of cells in culture, even
with supplementation. Conversely, VEGF164 EC displayed
constitutively high levels of VEGFR2, which increased with
increased exposure to hypoxia (Figure 1C), concomitant with
increased activation by tyrosine phosphorylation (Figure 1D).
Interestingly, VEGF188 has moderate levels of VEGFR2,
which do not increase with hypoxia, but this does not
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FIGURE 4 | VEGF isoform contribution to nitric oxide generation by endothelial cells through PI3 kinase/Akt signaling during hypoxia. (A) NO (x) levels in
cell conditioned medium of EC exposed to 21 or 1% O2 for 24 h, with or without 1 h of LY294002 pre-treatment at the indicated concentration. Data shown are
average ± SEM (n = 3); three wells, each containing cells isolated from 2 to 3 mice. *P < 0.05, **P < 0.005. (B) Western blot of whole cell extracts from endothelial
cells treated for 24 h at 21 or 1% O2 were probed with phospho-Akt at Ser473, total Akt, or β-actin antibodies. (C) Schematic representation of plausible differential
signaling in endothelial cells exclusively expressing VEGF164 or VEGF188.
compromise VEGFR2 phosphorylation: both VEGF164 and
VEGF188 have identical ratio of activated VEGFR2 which
is not altered by hypoxia, a phenomenon only observed in
EC expressing all isoforms (WT) (Figures 1C,D). This argues
that the differential accumulation of VEGFR2 protein relies
profoundly on VEGF164, whereas phosphorylation happens
downstream of either isoform, with the increase of VEGFR2
phosphorylation in response to hypoxia likely requiring the
concomitant expression of both, or even all, isoforms, as
suggested by the increase in P-VEGFR2/VEGFR2 ratio in
WT EC.
Functions downstream of VEGFR2 activation include survival
and proliferation, which, as expected, are higher in VEGF164 and
WT cells, whereas VEGF188 EC exhibit lower and unsustained
proliferation and increased apoptosis (Figures 1A,B).
Subsequent functional analyses confirmed VEGF164 to be
the isoform driving stability of endothelial monolayers, with
increased adhesion to matrices and EC-EC communication,
with significantly higher VE-cadherin levels correlating
with decreased paracellular permeability and, conversely,
increased barrier function, to both solutes and invading
cells (Figures 2, 3, Supplementary Figure 4). VEGF188 EC
showed almost opposite phenotypes, except in angiogenic
potential, as both EC isotypes are able to form networks
(Figure 3). However, VEGF188 EC have increased tube
formation in normoxia. This can be explained by the less
adhesive nature of these cells, which should render them
more likely to move and assemble. The fact that there is no
increase in tube formation in VEGF188 EC in response to
hypoxia, could be due to the fact that this isoform alone is not
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sufficient to drive increase in VEGFR2 levels and activation
(Figures 1C,D).
Finally, it has long been established that endothelial cells
are key regulators of vascular relaxation (by the production of
NO) (Vanhoutte, 1989; Cines et al., 1998), and interestingly,
are also the cells that produce the most potent vasoconstriction
signal (endothelin). Most vascular pathologies are associated
with impaired vascular relaxation, which potentiates shear stress
and accumulation of reactive oxygen species (which in turn
compromise NO synthesis) (Cines et al., 1998; Forstermann and
Munzel, 2006). NO homeostasis is a result of eNOS activity,
whereas iNOS can be activated in EC during physiological
insult, such as hypoxia (Branco-Price et al., 2012; Forstermann
and Sessa, 2012). We investigated if NO production happens
downstream of VEGF signaling, and saw significantly higher
levels of NO in VEGF188 cells, when compared to WT and
VEGF164 concomitant with increased P-Akt levels, known to
promote eNOS activity. Changes in P-Akt levels can shift the
homeostatic setpoint, and a biased ratio of VEGF188 can lead to
a more relaxed endothelium (Figure 4C).
It is implausible that VEGF120 has an autocrine role in
EC, and, as proposed in one of ours and others previous
studies, this isoform acts instead as a paracrine signal, which
can create a gradient and direct recruitment of other cells,
including endothelial cells from preexisting vessels (Grunstein
et al., 2000; Ruhrberg et al., 2002; Gerhardt et al., 2003). This is
corroborated by a significant increase in secretion of VEGF120
in hypoxia (Supplementary Figure 1), a signal that could drive
vessel sprouting and guidance toward oxygen deprived sites, such
as during injury, inflammation, tumorigenesis, or regeneration.
Taken together (Figure 4C) these data suggest that VEGF164
and VEGF188 are the isoforms with autocrine function in EC,
and likely act in coordination to maintain homeostasis. By
altering the ratio of VEGF164 to VEGF188, the endothelium can
respond to physiological demand by improving barrier function
(more VEGF164), increasing permeability (more VEGF188), or
assemble new vessels. This is relevant in physiological and in
clinical settings. Isoform-promiscuous approaches to treatment
can now be refined to address this more intricate level of control
of vascular function.
Our future work includes assessing the role of these isoforms
in other endothelial cell types, to identify endothelial-intrinsic
and organ-driven regulation of endothelial function, in health
and disease, as well as development.
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